Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

79.90
-0.9500-1.18%
Post-market: 79.900.00000.00%19:30 EDT
Volume:2.33M
Turnover:184.76M
Market Cap:7.05B
PE:-39.75
High:80.91
Open:79.58
Low:77.05
Close:80.85
52wk High:110.18
52wk Low:16.04
Shares:88.17M
Float Shares:80.98M
Volume Ratio:1.11
T/O Rate:2.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:7.38
PE(LYR):-40.45

Loading ...

Is Spyre Therapeutics (SYRE) Fully Priced Following Its $350 Million Equity Raise?

Simply Wall St.
·
Yesterday

Update: Spyre Shares Fall After Pricing $350 Million Stock Offering

MT Newswires Live
·
Oct 07

Spyre Therapeutics falls -8.4%

TIPRANKS
·
Oct 06

U.S. Stocks on the MOVE-MYR Group, Spyre Therapeutics, AMD

Reuters
·
Oct 06

Spyre Therapeutics Slips on $350 Mln Share Sale

Reuters
·
Oct 06

Spyre Therapeutics Shares Slip 1.7% Premarket After Co Prices $350 Million Stock Offering

THOMSON REUTERS
·
Oct 06

Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock

THOMSON REUTERS
·
Oct 06

Spyre Therapeutics - Prices Public Offering of 4,117,648 Shares at $85 Per Share

THOMSON REUTERS
·
Oct 06

Spyre Therapeutics Launches Underwritten Public Offering of Common Stock

Reuters
·
Oct 06

Spyre Therapeutics - Net Proceeds Intended for Advancing Programs and Spy072 Late-Stage Development

THOMSON REUTERS
·
Oct 06

Spyre Therapeutics Announces Proposed Public Offering of Its Common Stock

THOMSON REUTERS
·
Oct 06

Wells Fargo Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Oct 04

Spyre Therapeutics CFO Scott L. Burrows Disposes of USD 1.85 Million in Common Shares

Reuters
·
Oct 03

Spyre Therapeutics Grants Inducement Equity Awards of 21,424 Stock Options and 6,604 RSUs to New Hires

Reuters
·
Oct 03

Spyre Therapeutics Announces Grants of Inducement Awards

GlobeNewswire
·
Oct 03

Spyre Therapeutics Inc : Jonestrading Raises Target Price to $130 from $121

THOMSON REUTERS
·
Oct 01

Spyre Therapeutics Shares up 6.4% After Merck's Experimental Drug Succeeds in Skin Disease Trial

THOMSON REUTERS
·
Sep 30

Spyre Gains After Merck's Drug Succeeds in Skin Disease Trial

Reuters
·
Sep 30

Movement Alert|SPYRE THERAPEUTICS INC Rises 6.21% in Regular Trading, Trading at $89.915

Market Focus
·
Sep 30

Analysts Offer Insights on Healthcare Companies: Oncolytics Biotech (ONCY) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Sep 28